Inserting end-modified DNA fragments with CRISPR-Cas9 yields highest efficiency

University of Illinois researchers achieved the highest reported rates of inserting genes into human cells with the CRISPR-Cas9 gene-editing system, a necessary step for harnessing CRISPR for clinical gene-therapy applications.

By chemically tweaking the ends of the DNA to be inserted, the new technique is up to five times more efficient than current approaches. The researchers saw improvements at various genetic locations tested in a human kidney cell line, even seeing 65% insertion at one site where the previous high had been 15%.

Led by chemical and biomolecular engineering professor Huimin Zhao, the researchers published their work in the journal Nature Chemical Biology.

Researchers have found CRISPR to be an efficient tool to turn off, or "knock out," a gene. However, in human cells, it has not been a very efficient way to insert or "knock in" a gene.

"A good knock-in method is important for both gene-therapy applications and for basic biological research to study gene function," said Zhao, who leads the biosystems design theme at the Carl R. Woese Institute for Genomic Biology at Illinois. "With a knock-in method, we can add a label to any gene, study its function and see how gene expression is affected by cancer or changes in chromosome structure. Or for gene-therapy applications, if someone has a disease caused by a missing gene, we want to be able to insert it."

Searching for a way to increase efficiency, Zhao's group looked at 13 different ways to modify the inserted DNA. They found that small changes to the very end of the DNA increased both the speed and efficiency of insertion.

Then, the researchers tested inserting end-modified DNA fragments of varying sizes at multiple points in the genome, using CRISPR-Cas9 to precisely target specific sites for insertion. They found efficiency improved two to five times, even when inserting larger DNA fragments - the most difficult insertion to make.

We speculate that the efficiency improved so much because the chemical modification to the end stabilizes the DNA we are inserting. Normally, when you try to transfer DNA into the cell, it gets degraded by enzymes that eat away at it from the ends. We think our chemical addition protects the ends. More DNA is getting into the nucleus, and that DNA is more stable, so that's why I think it has a higher chance to be integrated into the chromosome."

Huimin Zhao, chemical and biomolecular engineering professor, University of Illinois

Zhao's group already is using the method to tag essential genes in gene function studies. They purposely used off-the-shelf chemicals to modify the DNA fragments so that other research teams could use the same method for their own genetic studies.

"We've developed quite a few knock-in methods in the past, but we never thought about just using chemicals to increase the stability of the DNA we want to insert," Zhao said. "It's a simple strategy, but it works."

Source:
Journal reference:

Yu, Y., et al. (2019) An efficient gene knock-in strategy using 5′-modified double-stranded DNA donors with short homology arms. Nature Chemical Biology. doi.org/10.1038/s41589-019-0432-1.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients